查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1595584

预防药物市场：按分销管道、按专业划分 - 2025-2030 年全球预测

Preventive Medicines Market by Distribution Channels (Diagnostic Centers, Hospitals), Specialty Areas (Aerospace Medicine, General Preventive Medicine, Occupational Medicine) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年预防药物市场价值为3,764.9亿美元，预计2024年将达到4,075.8亿美元，复合年增长率为8.74%，到2030年将达到6,769.8亿美元。

预防药物包括旨在预防疾病的各种药物、疫苗、补充品和生活方式干预措施。由于慢性病的流行、医疗费用的上升以及健康意识的增强，对预防性医疗保健的需求不断增加。最终用途涵盖感染疾病、慢性病管理、癌症预防、妇幼保健等，包括医院、诊所、研究机构和直接面向消费者的平台。该市场是由诊断技术的进步、医疗保健基础设施投资的增加以及远距远端医疗的日益普及等关键因素推动的。成长潜力在于免疫计画的扩大、用于自我监测的可穿戴技术的普及以及人工智慧与个人化预防策略的整合。

主要市场统计
基准年[2023] 3764.9亿美元
预测年份 [2024] 4075.8亿美元
预测年份 [2030] 6769.8亿美元
复合年增长率（%） 8.74%

新兴市场的最新机会包括开发针对新兴病原体的针对性疫苗、针对遗传特征量身定制的营养食品以及提供即时健康资料的行动医疗应用程式。公司可以透过投资研究和扩展其数位健康能力来利用这些优势。然而，监管障碍、高昂的研发成本和疫苗犹豫等挑战可能会阻碍成长。此外，低收入地区预防药物的供应和负担能力仍然是一个主要障碍。儘管有这些挑战，适合开拓的创新领域包括用于疾病预测的生物资讯学、植物来源疫苗以及应用 CRISPR 技术预防遗传疾病。

从策略上讲，公司将重点关注与高科技公司的合作，以加强精准医疗倡议，参与官民合作关係关係，以扩大对服务不足的市场的覆盖范围，并追求科学突破，以保持在研究的前沿。市场的性质是动态和竞争的，重点转向预防措施，不仅减少发病率，而且促进整体医疗保健。成功应对这些复杂因素、利用新技术并促进跨行业合作的公司将能够确保这个不断发展的行业的持续成长。

市场动态：揭示快速发展的预防药物市场的关键市场洞察

供需的动态交互作用正在改变预防医学市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 药品、医疗设备、治疗和手术的价格上涨
    • 製药公司对生产预防药物的兴趣增加
    • 传播预防医学教育的措施和活动
  • 市场限制因素
    • 预防药物区域确认缓慢
  • 市场机会
    • 协作市场生态系统
    • 支持定制处方笺的技术进步
  • 市场挑战
    • 缺乏引用预防药物的确切证据或研究

波特五力：驾驭预防药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解预防医学市场的外部影响

外部宏观环境因素在塑造预防药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解预防医学市场的竞争状况

对预防药物市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵预防药物市场供应商的绩效评估

FPNV定位矩阵是评估预防药物市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了预防药物市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，预防药物市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 药品、医疗设备、治疗和手术的价格上涨
      • 製药公司对生产预防药物的兴趣增加
      • 传播预防医学教育的措施和活动
    • 抑制因素
      • 预防性药物的鬆散区域检查
    • 机会
      • 协作市场生态系统
      • 技术进步支援制定客製化解决方案
    • 任务
      • 没有经过证实的证据或研究支持预防医学。
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依分销管道分類的预防药品市场

  • 诊断中心
  • 医院

第七章 预防医学专业市场

  • 航太医学
  • 综合预防医学
  • 工业医学
  • 公共卫生

第八章美洲预防医学市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区预防医学市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲、中东和非洲预防医学市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Aetna Inc.
  • Affymetrix, Inc
  • Cancer Prevention Pharmaceuticals, Inc
  • Dilon Technologies, Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • McKesson Corporation
  • Medtronic PLC
  • Merck & Co. Inc.
  • Myriad Genetics, Inc.
  • Myriad Women's Health, Inc.
  • Novo Nordisk A\S
  • Omada Health, Inc.
  • Omnicell, Inc.
  • Pfizer, Inc.
Product Code: MRR-031C6D6EB1CD

The Preventive Medicines Market was valued at USD 376.49 billion in 2023, expected to reach USD 407.58 billion in 2024, and is projected to grow at a CAGR of 8.74%, to USD 676.98 billion by 2030.

Preventive medicines encompass a broad range of pharmaceuticals, vaccines, supplements, and lifestyle interventions aimed at preventing diseases before they occur. The growing necessity for preventive healthcare is driven by rising chronic disease prevalence, increasing healthcare costs, and heightened awareness around health and wellness. Its application spans across infectious diseases, chronic disease management, cancer prevention, and maternal-child health, with end-use scope including hospitals, clinics, research institutes, and direct-to-consumer platforms. The market is propelled by key factors such as technological advancements in diagnostics, increased investment in healthcare infrastructure, and the growing implementation of telemedicine. Growth potential lies in expanding immunization programs, the proliferation of wearable tech for self-monitoring, and the integration of AI in personalized preventive strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 376.49 billion
Estimated Year [2024] USD 407.58 billion
Forecast Year [2030] USD 676.98 billion
CAGR (%) 8.74%

Latest opportunities in the market include developing targeted vaccines for emerging pathogens, nutraceuticals tailored to genetic profiles, and mobile health applications that offer real-time health data. Companies can capitalize on these by investing in research and expanding their digital health capabilities. However, challenges such as regulatory hurdles, high R&D costs, and vaccine hesitancy can impede growth. Furthermore, the accessibility and affordability of preventive medicines in low-income regions remain significant barriers. Despite these challenges, innovation areas ripe for exploration include bioinformatics for disease prediction, plant-based vaccines, and CRISPR technology applications for hereditary disease prevention.

Strategically, businesses should focus on collaborations with tech firms to enhance precision medicine initiatives, engage in public-private partnerships to improve reach in underserved markets, and continuously invest in research to stay at the forefront of scientific breakthroughs. The nature of the market is dynamic and competitive, with emphasis shifting towards preventive measures that not only reduce incidence rates but also promote holistic health management. Companies that successfully navigate these complex factors, leveraging emerging technologies and fostering cross-industry collaborations, will likely secure sustainable growth in this evolving sector.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preventive Medicines Market

The Preventive Medicines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prices of medicines, medical devices, medical treatments, and surgical procedures
    • Increasing interest of pharma companies in manufacturing of preventive medicine
    • Initiatives and events to spread education about the preventive medicines
  • Market Restraints
    • Loosely defined regional confirmations referring to preventive drug
  • Market Opportunities
    • Collaborative market ecosystem
    • Technology advancement to support prescription of tailor made solutions
  • Market Challenges
    • Absence of proven evidences or studies citing preventive medicine

Porter's Five Forces: A Strategic Tool for Navigating the Preventive Medicines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preventive Medicines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preventive Medicines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preventive Medicines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preventive Medicines Market

A detailed market share analysis in the Preventive Medicines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preventive Medicines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preventive Medicines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Preventive Medicines Market

A strategic analysis of the Preventive Medicines Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Preventive Medicines Market, highlighting leading vendors and their innovative profiles. These include Aetna Inc., Affymetrix, Inc, Cancer Prevention Pharmaceuticals, Inc, Dilon Technologies, Inc., Eli Lilly and Company, GlaxoSmithKline PLC, McKesson Corporation, Medtronic PLC, Merck & Co. Inc., Myriad Genetics, Inc., Myriad Women's Health, Inc., Novo Nordisk A\S, Omada Health, Inc., Omnicell, Inc., and Pfizer, Inc..

Market Segmentation & Coverage

This research report categorizes the Preventive Medicines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Distribution Channels, market is studied across Diagnostic Centers and Hospitals.
  • Based on Specialty Areas, market is studied across Aerospace Medicine, General Preventive Medicine, Occupational Medicine, and Public Health.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prices of medicines, medical devices, medical treatments, and surgical procedures
      • 5.1.1.2. Increasing interest of pharma companies in manufacturing of preventive medicine
      • 5.1.1.3. Initiatives and events to spread education about the preventive medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Loosely defined regional confirmations referring to preventive drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative market ecosystem
      • 5.1.3.2. Technology advancement to support prescription of tailor made solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Absence of proven evidences or studies citing preventive medicine
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Preventive Medicines Market, by Distribution Channels

  • 6.1. Introduction
  • 6.2. Diagnostic Centers
  • 6.3. Hospitals

7. Preventive Medicines Market, by Specialty Areas

  • 7.1. Introduction
  • 7.2. Aerospace Medicine
  • 7.3. General Preventive Medicine
  • 7.4. Occupational Medicine
  • 7.5. Public Health

8. Americas Preventive Medicines Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Preventive Medicines Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Preventive Medicines Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Aetna Inc.
  • 2. Affymetrix, Inc
  • 3. Cancer Prevention Pharmaceuticals, Inc
  • 4. Dilon Technologies, Inc.
  • 5. Eli Lilly and Company
  • 6. GlaxoSmithKline PLC
  • 7. McKesson Corporation
  • 8. Medtronic PLC
  • 9. Merck & Co. Inc.
  • 10. Myriad Genetics, Inc.
  • 11. Myriad Women's Health, Inc.
  • 12. Novo Nordisk A\S
  • 13. Omada Health, Inc.
  • 14. Omnicell, Inc.
  • 15. Pfizer, Inc.

LIST OF FIGURES

  • FIGURE 1. PREVENTIVE MEDICINES MARKET RESEARCH PROCESS
  • FIGURE 2. PREVENTIVE MEDICINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PREVENTIVE MEDICINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PREVENTIVE MEDICINES MARKET DYNAMICS
  • TABLE 7. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY AEROSPACE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY GENERAL PREVENTIVE MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY OCCUPATIONAL MEDICINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PREVENTIVE MEDICINES MARKET SIZE, BY PUBLIC HEALTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 18. ARGENTINA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 20. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 22. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 24. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES PREVENTIVE MEDICINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. AUSTRALIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 34. CHINA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 36. INDIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 38. INDONESIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 40. JAPAN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 42. MALAYSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 44. PHILIPPINES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 46. SINGAPORE PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 48. SOUTH KOREA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 50. TAIWAN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 52. THAILAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 54. VIETNAM PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. DENMARK PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 61. EGYPT PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 63. FINLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 65. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 67. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 69. ISRAEL PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 71. ITALY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 73. NETHERLANDS PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 75. NIGERIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 77. NORWAY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 79. POLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 81. QATAR PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 83. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 85. SAUDI ARABIA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 89. SPAIN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 91. SWEDEN PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 93. SWITZERLAND PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 95. TURKEY PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED ARAB EMIRATES PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM PREVENTIVE MEDICINES MARKET SIZE, BY SPECIALTY AREAS, 2018-2030 (USD MILLION)
  • TABLE 101. PREVENTIVE MEDICINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 102. PREVENTIVE MEDICINES MARKET, FPNV POSITIONING MATRIX, 2023